MaxCyte, Inc.

NasdaqGS MXCT

MaxCyte, Inc. Price to Book Ratio (P/B) on February 06, 2025: 2.12

MaxCyte, Inc. Price to Book Ratio (P/B) is 2.12 on February 06, 2025, a -2.14% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

MaxCyte, Inc. 52-week high Price to Book Ratio (P/B) is 2.41 on January 21, 2025, which is 14.09% above the current Price to Book Ratio (P/B).
MaxCyte, Inc. 52-week low Price to Book Ratio (P/B) is 1.53 on November 18, 2024, which is -27.90% below the current Price to Book Ratio (P/B).
MaxCyte, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.92.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: MXCT

MaxCyte, Inc.

CEO	Mr. Maher Masoud
IPO Date	July 30, 2021
Location	United States
Headquarters	9713 Key West Avenue
Employees	143
Sector	Healthcare
Industries Biotechnology 3D Printing

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key trends

Past 5 years